

## Declaration of Interests Register

**TA Committee D**

**Publication Date: 13/05/2020**

**Topic: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer [ID1338]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Amanda Matse-Orere	TAC D Committee Member	Direct - financial	Works for a comparator company	NA	06/01/2020	NA	It was agreed that this declaration <b>would</b> prevent Amanda Matse-Orere from participating in this section of the meeting.
Professor Fiona Blackhall	Clinical Expert	Direct - financial	Research funds to institution for trials of ALK inhibitors including lorlatinib but no direct personal funding received	NA	23/08/2019	NA	It was agreed that this declaration <b>would not</b> prevent Professor Blackhall from participating in this section of the meeting.
Dr Alastair Greystoke	Clinical Expert	Direct - financial	Previous consultancy and speakers fees from Pfizer as to the management of ALK fusion NSCLC	NA	05/06/2019	NA	It was agreed that this declaration <b>would not</b> prevent Dr Greystoke from participating in this section of the meeting.